专利信息

首页 1 2 3 4 5 6 下页尾页共 1991 条记录, 当前第1/200页。

专利标题：Process for the preparation of crystalline modifications for use in the preparation of esomeperazole sodium salt

专利权人：ASTRAZENECA AB;

The present invention relates to a new process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt. Further the present invention also relates to the use of the new crystal modifications for the treatment of gastrointestinal disorders pharmaceutical compositions containing them as well as the crystal modifications as such.

专利标题：9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators

专利权人：ASTRAZENECA AB;

The present invention relates to a novel process for preparing a novel form of the (-)-enantiomer of 5-methoxy-2-ÄÄ(4-methoxy-35-dimethyl-2-pyridinyl)-methylÜsulfinylÜ-1H -benzimidazole i.e. S-omeprazole. More specifically it relates to a process for preparing trihydrate of magnesium salt of S-omeprazole. Furthermore the present invention also relates to new intermediates used in that process.

专利标题：Novel ticagrelor co - crystal

专利权人：ASTRAZENECA AB;

The present invention relates to a novel co-crystal of the compound of formula (I): wherein the co-former molecule is acetyl salicylic acid, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the prevention of arterial thrombotic complications in patients with coronary artery, cerebrovascular or peripheral vascular disease and to methods of treating such diseas...

专利标题：New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt

专利权人：ASTRAZENECA AB;

专利标题：Bilayer Tablet Formulations

The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.

专利标题：Therapeutic treatment

专利权人：ASTRAZENECA AB;

专利标题：(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives

专利权人：ASTRAZENECA AB;

The present invention relates to compounds of formula (I) The compounds act via antagonism of the CCR2b receptor and may be used to treat inflammatory disease and/or neuropathic pain.

专利标题：Novel form of s-omeprazole

专利权人：ASTRAZENECA AB;

专利标题：(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives

专利权人：ASTRAZENECA AB;

The present invention relates to compounds of formula (I) The compounds act via antagonism of the CCR2b receptor and may be used to treat inflammatory disease and/or neuropathic pain.

当前查询条件: [专利权人组] 包含 '阿斯利康'

	查询范围	在当前结果中查询
!	专利类型	发明实用新型外观设计
!	公开号			CN1234
!	申请号			CN1234
!	专利标题		扩展	PHARMA
!	专利权人		扩展	pfizer
	发明人
!	申请日			yyyymmdd
!	公开日			yyyymmdd
	优先权号
!	摘要		扩展	PHARMA
	IPC			A01B

1. US8658799B2	2014/2/25	US11/570717	2005/6/20
专利标题：Process for the preparation of crystalline modifications for use in the preparation of esomeperazole sodium salt 专利权人：ASTRAZENECA AB; The present invention relates to a new process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt. Further the present invention also relates to the use of the new crystal modifications for the treatment of gastrointestinal disorders pharmaceutical compositions containing them as well as the crystal modifications as such.

2. EP2132209B1	2014/2/12	EP20080718797	2008/3/19
专利标题：9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators 专利权人：ASTRAZENECA AB;

3. ES2195345T7	2014/1/15	ES19980926005T	1998/5/25
专利标题：专利权人：ASTRAZENECA AB; The present invention relates to a novel process for preparing a novel form of the (-)-enantiomer of 5-methoxy-2-ÄÄ(4-methoxy-35-dimethyl-2-pyridinyl)-methylÜsulfinylÜ-1H -benzimidazole i.e. S-omeprazole. More specifically it relates to a process for preparing trihydrate of magnesium salt of S-omeprazole. Furthermore the present invention also relates to new intermediates used in that process.

4. AU2012264432A1	2014/1/9	AU20120264432	2012/5/31
专利标题：Novel ticagrelor co - crystal 专利权人：ASTRAZENECA AB; The present invention relates to a novel co-crystal of the compound of formula (I): wherein the co-former molecule is acetyl salicylic acid, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the prevention of arterial thrombotic complications in patients with coronary artery, cerebrovascular or peripheral vascular disease and to methods of treating such diseas...

5. KR20130140918A	2013/12/24	KR20137032748	2005/6/20
专利标题：New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt 专利权人：ASTRAZENECA AB; The present invention relates to a new process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt. Further the present invention also relates to the use of the new crystal modifications for the treatment of gastrointestinal disorders pharmaceutical compositions containing them as well as the crystal modifications as such.

6. US2013330406A1	2013/12/12	US201313965879	2013/8/13
专利标题：Bilayer Tablet Formulations 专利权人：ASTRAZENECA UK LTD [GB];SQUIBB BRISTOL MYERS CO [US]; The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.

7. CN103442708A	2013/12/11	CN2012816297	2012/4/2
专利标题：Therapeutic treatment 专利权人：ASTRAZENECA AB;

8. US20130289043A1	2013/10/31
专利标题：(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives 专利权人：ASTRAZENECA AB; The present invention relates to compounds of formula (I) The compounds act via antagonism of the CCR2b receptor and may be used to treat inflammatory disease and/or neuropathic pain.

9. EP0984957B3	2013/9/18	EP19980926005	1998/5/25
专利标题：Novel form of s-omeprazole 专利权人：ASTRAZENECA AB;

10. AU2009327575B2	2013/7/4
专利标题：(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives 专利权人：ASTRAZENECA AB; The present invention relates to compounds of formula (I) The compounds act via antagonism of the CCR2b receptor and may be used to treat inflammatory disease and/or neuropathic pain.

下载范围

下载内容